Imagene develops an AI platform for biomarkers identification and response prediction that delivers real-time molecular analysis using only a digitized biopsy image.
We drive a new approach for treatment response prediction that encapsulates the uniqueness of each patient, bringing cancer care closer to reaching the full potential of precision medicine.
Imagene's technology classifies patterns that cannot be seen by the human eye, evolving genomics, proteomics, and spatial insights to understand better the recurrence of specific cancers and their resistance mechanisms; this enables better stratification of patients in clinical trials and the discovery of novel targets for new drugs. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide to improve the overall quality of care and accelerate the drug development process.
Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts.